MedTrace Logo

Impact of CES1 Genotype on Metabolism of Methylphenidate

NCT02147535 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2014-10-13

No results posted yet for this study

Summary

The purpose of this study is to determine whether differences in the gene coding for the liver enzyme carboxylesterase 1 (CES1) means differences in the metabolism of methylphenidate, a CES1 dependent drug.

Conditions

  • Carboxylesterase 1 (CES1) Genotype
  • CES1 Activity

Interventions

DRUG

Methylphenidate

10 mg as a single dose followed by one blood sample 3 hours post-dose

Sponsors & Collaborators

  • The Ministry of Science, Technology and Innovation, Denmark

    collaborator OTHER_GOV

  • Mental Health Centre Sct. Hans (Denmark)

    collaborator UNKNOWN

  • University of Copenhagen

    collaborator OTHER

  • The Leiden Academic Center for Drug Research (LACDR)

    collaborator UNKNOWN

  • Duke University

    collaborator OTHER

  • Bispebjerg Hospital

    lead OTHER

Principal Investigators

  • Claus Stage, M.D. · Department of Clinical Pharmacology, Bispebjerg University Hospital

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02147535 on ClinicalTrials.gov